DCVax-L

July 8, 2026: Northwest Biotherapeutics (OTCQB: NWBO) reported a scientific presentation at the 2026 British Neuro-Oncology Society (BNOS) Annual Meeting in which its CTO presented updated survival analyses from the Phase III trial of DCVax-L in newly diagnosed glioblastoma (GBM). Independent statisticians applied individual patient-level data (IPD)-based methods—propensity score matching (PSM) and inverse probability weighting (IPW)—after the company obtained IPD from several major randomized controlled trials in ndGBM to enable more precise matching versus controls than the original cohort-level analysis.

Across PSM analyses of three ndGBM RCTs, the median survival advantage with DCVax-L was 4.9–6.3 months in two RCTs and 3.4–3.7 months in a third; hazard ratios ranged 0.69–0.77 with p values 0.004–0.027. IPW analyses showed a median survival advantage of 3.4–4.3 months. Sensitivity analyses (E-values and Rosenbaum’s Gamma) were presented as indicating the observed effect was not attributable to hidden imbalances.

Regulatory status: the company stated it has submitted a UK MAA for DCVax-L and that it is currently under review. Other program update: DCVax-Direct completed a 40-patient Phase I trial and the company plans to pursue Phase II trials this year.